Skip to menu

Supporting Healthy Eye Function

 

Nutrition research shows that Enzogenol supports healthy eye function with age.

The effects of Enzogenol on parameters of eye health were studied in a randomised controlled trial by Dr. Nigel Gilchrist of the Christchurch Geriatric Medical Research Trust at the Princess Margaret Hospital, Christchurch, New Zealand. In this trial, 60 participants from local rest-homes with an average age of 82 years were assigned to treatment and control groups. Enzogenol was found to be very well tolerated with no adverse reactions and normal laboratory measures of all safety related blood parameters. The results indicated that Enzogenol was associated with beneficial effects for eye function shown below.

Acuity of vision, a combined measure of near and distant vision declined five times faster in the control group compared to the Enzogenol group over the 6 months trial period. Distant vision improved significantly after 6 months of taking Enzogenol compared to controls. There were less people experiencing deterioration in eye sight, and more people with stable and better vision.

These findings showed that taking Enzogenol supported healthy eye function. In particular, this support was effective in a population of older people that commonly experience difficulties with their eye sight.

 

 

 

 

eye1.jpg  eye2.jpg

 

 

The effect of Enzogenol on parameters of eye health

 


Enzogenol® pine bark extract is a dietary supplement and food ingredient produced by water extraction of Pinus radiata. We present production method, composition, and safety data from rat and dog toxicological and human clinical studies. The dry powder contains proanthocyanidins (>80%), taxifolin (1–2%), other flavonoids and phenolic acids (up to 8%), and carbohydrates (5–10%). Reverse mutation assays showed lack of mutagenic activity. Single and 14-day repeat dosing in rats and dogs had no influence on body weight, feed consumption, blood chemistry, and haematology at any dose level. There were no treatment related findings on gross and detailed necroscopy, organ weights, organ weight ratios and histology. The only adverse events were emesis and diarrhoea in dogs occurring mainly in un-fed condition and at the highest dose level in a total of 18% of applications. The MTD and NOAEL in the present rat and dog studies were 2500 and 750 mg/kg/day, respectively. Consumption of 480 mg/day for 6 months and 960 mg/day for 5 weeks in two human studies showed Enzogenol® had no adverse influence on liver and kidney function, haematology, and did not cause any adverse events. Our studies indicate lack of toxicity of Enzogenol® and support safe use as a food ingredient.